Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Tecentriq plus Avastin First Immunotherapy Combination Approved as First-Line Treatment of Advanced Liver Cancer

August 2020 – Immunotherapy

On May 29, 2020, the FDA approved the combination of 2 immunotherapies, Tecentriq (atezolizumab; from Genentech), a PD-L1 inhibitor, and Avastin (bevacizumab; from Genentech), a VEGF inhibitor, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma, or liver cancer, who have not received systemic therapy.

Tecentriq and Avastin have each previously been approved alone or in combination with other therapies for multiple types of cancers. This is their first approval for liver cancer, and it is the first immunotherapy regimen to be approved by the FDA as first-line treatment for advanced liver cancer.

Before this approval, the standard therapy for first-line treatment of unresectable or metastatic liver cancer was Nexavar (sorafenib), a kinase inhibitor. It is estimated that more than 42,000 Americans will be diagnosed with liver cancer in 2020. Hepatocellular carcinoma is the most common type of liver cancer, accounting for about 75% of all liver cancer cases in the United States.

“The results of the IMbrave150 study are really transformative for patients with advanced liver cancer, one of the few cancers with a rising death rate and limited options in the first-line setting,” said Richard S. Finn, MD, Director, Signal Transduction and Therapeutics Program, UCLA Jonsson Comprehensive Cancer Center. “For the first time we have a regimen that markedly improves survival over sorafenib, the standard of care for first-line hepatocellular carcinoma since 2007, and offers patients the opportunity for improved disease control with a favorable tolerability profile,” Dr. Finn said.

The FDA approved this immunotherapy combination for advanced liver cancer based on results from the phase 3 IMbrave150 clinical trial. The study included 501 patients with unresectable or metastatic liver cancer who had not received systemic therapy and were divided into 2 groups.

The immunotherapy combination improved survival by 42% compared with Nexavar, and the average time without disease progression was 6.8 months with the immunotherapy combination versus 4.3 months with Nexavar. This resulted in a risk reduction of disease progression or death by 41% with immunotherapy. After 12 months of therapy, the survival with immunotherapy was 67.5% compared with 54.6% with Nexavar.

IMbrave150 is the first phase 3 clinical trial of immunotherapy to show an improvement in survival compared with Nexavar in patients with unresectable or metastatic liver cancer.

The most common serious side effects were gastrointestinal bleeding, infections, and fever.

Recommended For You